Pemigatinib, developed by Incyte Corporation, was approved for marketing by the U.S. Food and Drug Administration (FDA) in April 2020 and launched in China in April 2022. It has not been included in China's national medical insurance system. As an effective therapeutic drug for specific types of cancer, it is indicated for the treatment of adult patients with metastatic or unresectable cholangiocarcinoma. Patients can purchase this drug through channels such as hospitals and pharmacies.

Formal Purchase Channels for Pemigatinib

When seeking pemigatinib, a crucial therapeutic drug, understanding and following formal purchase channels is not only related to the authenticity of the drug but also directly affects the patient's treatment effect and life safety.

Purchase with a Hospital Prescription

The most direct and safe way to purchase pemigatinib is through the formal channels of a hospital. Under the guidance of a professional doctor, patients need to undergo a detailed disease assessment, after which the doctor will issue a prescription for pemigatinib. Patients can use the prescription to buy genuine pemigatinib at the hospital pharmacy or designated cooperative pharmacies.

Avoid Informal Channels

When purchasing pemigatinib, patients must be alert to informal channels, such as unauthorized online stores and personal transfers. The source of drugs from these channels is unknown, and there may be counterfeit or shoddy products, which seriously threaten the patient's health. Patients should resolutely resist the temptation of informal channels and insist on purchasing pemigatinib through formal channels.

Precautions for Pemigatinib Use in Special Populations

Although pemigatinib has significant efficacy in treating specific cancers, extra caution is required when using it in special populations.

Use in Elderly Patients

Due to the decline in physical functions, elderly patients may have reduced ability to metabolize and excrete drugs. When using pemigatinib, doctors will adjust the dosage according to the specific conditions of elderly patients and conduct close monitoring. Elderly patients should take the drug as prescribed by the doctor and must not increase, decrease the dosage or discontinue the drug on their own to avoid adverse reactions.

Use in Pregnant and Lactating Women

Pemigatinib may pose potential hazards to fetuses and infants. Pregnant and lactating women are strictly prohibited from using pemigatinib. For women with fertility plans, effective contraceptive measures should be taken during the use of pemigatinib, and they should consult a doctor for advice on pregnancy preparation after discontinuing the drug.

Dietary Contraindications and Recommendations for Pemigatinib

During the administration of pemigatinib, reasonable dietary adjustments are of great significance for improving the treatment effect and reducing adverse reactions.

Dietary Contraindications

Patients should avoid consuming foods that may affect the efficacy of pemigatinib, such as certain foods containing specific enzyme-inhibiting components. They should also avoid spicy, greasy, and irritating foods to prevent increasing the burden on the gastrointestinal tract and affecting the absorption and utilization of the drug. If you have any other questions, you can click to consult online for free.

Dietary Recommendations

To enhance the body's resistance, patients should consume more foods rich in protein, vitamins, and minerals, such as lean meat, fish, eggs, fresh vegetables, and fruits. These foods help provide the nutrients needed by the body and support the body's recovery during the treatment process.

Reasonable dietary adjustments are also important measures to improve the treatment effect and reduce adverse reactions.